Fig. 2

Cost-effectiveness acceptability curves for sofosbuvir/velpatasvir versus the status-quo (Scenario 1: originator prices) (a) and for sofosbuvir/daclatasvir versus the status-quo (Scenario 2: generic prices) (b) in Cameroon, Côte d’Ivoire and Senegal. The colored vertical lines (green, red and blue) indicate the cost-effectiveness thresholds of 0.5 times the GDP/capita in 2017 for each of the three study countries (i.e., US$683.5 in Senegal, US$711 in Cameroon, US$778.5 in Côte d’Ivoire, respectively). The cost-effectiveness acceptability curves show the probability that the preferred regimen in each scenario (i.e., sofosbuvir/velpatasvir in scenario 1 (a) and sofosbuvir/daclatasvir in scenario 2 (b)) is cost-effective compared with the status quo at various cost-effectiveness thresholds ranging from US$0 to US$1500/QALY. The green, red and blue curves correspond, respectively, to Senegal, Cameroon and Côte d’Ivoire. Abbreviations: GDP: Gross Domestic Product; ICER: Incremental cost-effectiveness ratio; QALYs: Quality adjusted Life-years